EXCLUSIVE: eFFECTOR, Locust Walk Acquisition CEOs On SPAC Deal, Drug Pipeline
Clinical-stage biopharmaceutical company eFFECTOR Therapeutics is set to go public via the special purpose acquisition company Locust Walk Acquisition Corp (NASDAQ: LWAC) with an enterprise value of $419 million.
